RegulationPriority Review (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (South Korea), Priority Review (Japan)

Structure/Sequence

Sequence Code 9474006L

Source: *****

Sequence Code 9474023H

Source: *****

Clinical Trials associated with Rozanolixizumab

NCT07465289

/ Not yet recruitingPhase 3

A Phase 3, Open-Label, Extension Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

The purpose of the study is to assess the long-term safety and efficacy of rozanolixizumab in adult study participants with ocular myasthenia gravis.

Start Date27 Jul 2026

Sponsor / Collaborator

UCB Biopharma SRL

NCT07570589

/ RecruitingNot ApplicableIIT

An Observational, Prospective, Multicenter, Open-label Study to Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab)

Generalized Myasthenia Gravis (gMG) is a rare autoimmune disease (a disease in which the body attacks its own tissues) that causes muscle weakness and significant fatigue.
Current treatments (corticosteroids, plasma exchange, intravenous immunoglobulin infusions) improve symptoms in many patients. However, many continue to suffer from fatigue and fatigability that are not well measured by standard tools. Moreover, these treatments can cause significant long-term side effects, reducing quality of life.
New treatments such as Rozanolixizumab (ROZ) are now available. They act rapidly and are well tolerated, allowing better symptom control while reducing the risks associated with conventional treatments.
To properly evaluate these new treatments, it is essential to understand patients' perspectives on their effectiveness. The scales used by physicians do not always capture all the symptoms experienced by patients, particularly fatigability. This is why a new tool has been developed: the MG symptoms PRO. This questionnaire allows patients to assess their own symptoms (fatigue, weakness of the eyes, mouth, breathing, muscle fatigability) in detail.
This research aims to better understand the effectiveness of treatments from the patients' perspective in order to improve their care.
The goal of the study is to evaluate the impact of Rozanolixizumab administration in real-world practice through the MG symptoms PRO questionnaire. This is an observational study, meaning that the medication is prescribed by the physician according to current regulations, and the study simply collects routine medical data during your follow-up, over a period of approximately 9 months.

Start Date15 Jun 2026

Sponsor / Collaborator

Centre Hospitalier Universitaire de Nice

NCT07463521

/ RecruitingPhase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

The purpose of the study is to demonstrate the efficacy, safety and tolerability of rozanolixizumab compared with placebo in the treatment of adult study participants with Ocular Myasthenia Gravis.

Start Date27 May 2026

Sponsor / Collaborator

UCB Biopharma SRL

100 Clinical Results associated with Rozanolixizumab

100 Translational Medicine associated with Rozanolixizumab

100 Patents (Medical) associated with Rozanolixizumab

Literatures (Medical) associated with Rozanolixizumab

01 Oct 2026·PHARMACOLOGY & THERAPEUTICS

Nipocalimab and other FcRn blockers in neuromuscular disorders

Review

Author: Khateb, Mohamed ; Bril, Vera

Neonatal Fc receptor (FcRn) inhibition represents a novel and targeted therapeutic approach for autoimmune neuromuscular disorders driven by pathogenic IgG autoantibodies. Nipocalimab is one of those, and it is a fully human, high-affinity IgG1 monoclonal antibody that blocks FcRn-IgG interactions, thereby accelerating degradation of IgG while sparing other immunoglobulin subtypes and cellular immune responses. This selective mechanism offers clear advantages over conventional immunosuppressive and immunomodulation therapies, like intravenous immunoglobulin, plasma exchange, steroidal and nonsteroidal immunosuppressants, and B-cell-depleting agents, including rapid onset of action, reversibility, and a favorable safety profile. Clinical evidence is most robust in generalized myasthenia gravis (MG), where phase II and III randomized trials demonstrated significant, dose-dependent reductions in MG-ADL and QMG scores, rapid clinical responses, and acceptable tolerability compared to placebo. Efficacy outcomes were broadly similar with all FcRn inhibitors, including efgartigimod and rozanolixizumab, establishing FcRn blockade as an effective strategy in antibody-mediated MG. Beyond MG, ongoing studies are evaluating nipocalimab in chronic inflammatory demyelinating polyneuropathy (CIDP), while efgartigimod has already shown significant relapse-prevention benefits. In contrast, FcRn inhibition appears ineffective in multifocal motor neuropathy, likely reflecting its predominantly IgM-mediated pathophysiology. Emerging data also suggest a potential role for FcRn inhibitors in immune-mediated myopathies, particularly those driven by IgG autoantibodies, although evidence remains sparse and preliminary. Overall, FcRn inhibition-and nipocalimab in particular-offers a promising, mechanism-based treatment paradigm across a spectrum of IgG-mediated neuromuscular diseases, with ongoing trials expected to further refine its clinical role, optimal indications, and long-term safety.

01 Aug 2026·CELLULAR IMMUNOLOGY

The uptake, intracellular trafficking and recycling of FcRn-blocking therapeutics in human endothelial cells in vitro

Article

Author: Cole, Suzanne L ; D'Hooghe, Lena E ; Singhvi-Hanns, Laura A ; Sirina, Julija ; Holliday, Nicholas D ; Stoddart, Leigh A ; Shock, Anthony

The neonatal Fc receptor (FcRn) recycles immunoglobulin G (IgG) in cells and is responsible for the long half-life of IgG relative to other plasma proteins. FcRn also recycles pathogenic IgG autoantibodies and is the target for several new targeted therapeutic agents in IgG autoantibody-driven disorders. These therapeutics include rozanolixizumab, a high-affinity monoclonal antibody that directly blocks the IgG binding site on FcRn in a pH-independent manner. This study explored the impact of these molecular characteristics on rozanolixizumab's cellular uptake, endosomal trafficking and recycling. Another anti-FcRn therapeutic, the Fc fragment MST-HN IgG Fc (an analog of efgartigimod), a competitive antagonist with weaker affinity and pH-dependent binding to FcRn, was included for comparison. Using high-content imaging methods in human umbilical vein endothelial cells (HUVECs), a time- and concentration-dependent uptake of fluorescently labeled rozanolixizumab into intracellular compartments was observed. Uptake was rapid, pH-independent, and competed out with unlabeled inhibitor, supporting a receptor-mediated mechanism. Conversely, uptake of MST-HN IgG Fc was slower and required higher concentrations to detect uptake, which was pH-dependent, not competed out with unlabeled inhibitor, and occurred with similar potency in cells that did not express FcRn, suggesting a receptor-independent mechanism such as fluid phase pinocytosis. Using Rab proteins associated with different endosomal compartments, FcRn inhibitors appeared to traffic through recycling compartments in a similar manner in HUVECs, and their return to the cell surface in FcRn-transfected cells occurred with similar kinetics. These data demonstrate the impact of different structural features of FcRn inhibitors on functional outcomes on cells in vitro.

01 Aug 2026·MUSCLE & NERVE

Non‐Cyclic Rozanolixizumab Administration in Complex Generalized Myasthenia Gravis

Article

Author: Fanny Duval ; Marlène Barnay ; Marie-Hélène Violleau ; Diane Beauvais ; Guilhem Sole ; Marc Abi Aoun ; Stéphane Mathis

ABSTRACT:

Introduction/Aims:

Rozanolixizumab, an inhibitor of the neonatal Fc receptor (FcRn), is used to treat patients with generalized myasthenia gravis (gMG) refractory to standard therapies. However, the approved six‐week cyclic regimen may be associated with a “wearing‐off” effect and disease fluctuations. We evaluated the non‐cyclic administration of rozanolixizumab in patients with complex gMG.

Methods:

We retrospectively studied eight patients with anti–acetylcholine receptor antibody–positive complex gMG treated at Bordeaux University Hospital. “Complex” was defined by refractoriness, contraindications, intolerance to immunosuppressants or highly active MG . Patients transitioned to weekly or fortnightly rozanolixizumab after relapse during intermittent therapy. The primary outcome was ≥ 2‐point improvement in Myasthenia Gravis Activities of Daily Living ( MG ‐ ADL ) score at 3 months. Clinical data and serum immunoglobulin G ( IgG ) levels were collected at baseline, 3, 6, and 12 months.

Results:

The cohort (mean age 70.5 years; 75% female) had a mean baseline MG ‐ ADL score of 10.8, which improved rapidly to 4.1 at 3 months. Hospitalization days dropped from 15.8/month pre‐treatment to zero by 6–12 months. Corticosteroids were tapered from 30.3 to 13.3 mg/day at 1 year. Mean serum IgG levels declined by almost 50% and stabilized. Only one discontinuation occurred due to gastrointestinal symptoms; no serious infections or severe adverse events were observed.

Discussion:

Fortnightly rozanolixizumab yielded sustained clinical benefits, reduced hospitalizations, and enabled steroid tapering in complex gMG patients. This approach may prevent cyclical relapses seen with intermittent dosing. Larger studies are needed to confirm efficacy and long‐term safety.

News (Medical) associated with Rozanolixizumab

12 Jun 2026

·www.prnewswire.com

Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 11, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today announced the appointment of Dr. Dhavalkumar Patel as Scientific Advisor. Dr. Patel brings an outstanding track record of therapeutic innovation spanning over two decades in industry and academia. He is currently Executive Vice President and Chief Scientific Officer of Sana Biotechnology. Prior to joining Sana Biotechnology in 2024, Dr. Patel served as Executive Vice President and Chief Scientific Officer of UCB, where he and his teams contributed to the registration of bimekizumab (Bimzelx®), rozanolixizumab (Rystiggo®) and zilucoplan (Zilbrysq®). Prior to UCB, he spent 10 years at Novartis, most recently as the Head of Research of the Novartis Institutes for BioMedical Research (NIBR) Europe. During his tenure, he led research in the autoimmune, transplantation, and inflammation disease areas, contributing to the registration of secukinumab (Cosentyx®), fingolimod (Gilenya®), siponimod (Mayzent®), canakinumab (Ilaris®), everolimus (Zortress®/Certican®, Afinitor®), leniolisib (Joenja®), and iptacopan (Fabhalta®) in multiple indications. He was also an Entrepreneur in Residence at the Novartis Venture Fund. Dr. Patel served as a member of the Board of Directors of Inflazome prior to its acquisition by Roche in 2020. He currently serves on the Boards of Directors for Priothera, Quell Therapeutics, and RE-AIM Therapeutics, and serves as Chair of the Board of Directors for Mimetas BV. Prior to joining industry in 2006, Dr. Patel was an Eminent Professor of Medicine, Chief of Rheumatology, Allergy and Clinical Immunology, and Director of the Thurston Arthritis Research Center at the University of North Carolina in Chapel Hill. He also spent nine years at the Duke University School of Medicine, culminating in his position as the Chief of the Division of Allergy and Immunology. Dr. Patel received his B.S., M.D., and Ph.D. in Microbiology and Immunology from Duke University, and is board certified in internal medicine, rheumatology, and allergy & immunology. "We are thrilled to welcome Dr. Patel to our Scientific Advisory Board," said Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed. "His outstanding combination of deep immunological science, proven drug development success, and board-level strategic insight will be a tremendous asset to us. We look forward to his guidance as we continue to build a leading immunology pipeline." "I am honored to join Harbour BioMed as a Scientific Advisor," said Dr. Dhavalkumar Patel. "Harbour BioMed has built a compelling portfolio of novel antibody candidates targeting key immune pathways, and I believe the company is well-positioned to make meaningful progress in areas of high unmet medical need. I look forward to working closely with the team to help advance these programs from discovery through development and ultimately to patients." About Harbour BioMed Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas. The Company is building a robust portfolio and differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions. Our proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. The HCAb-based Antibody Plus technology (HCAb PLUSTM) provides comprehensive modality solutions for the development of innovative multi-specific medicines in different disease areas. Additionally, building upon the Harbour Mice® platform, Harbour BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-mAtrIxTM AI platform, accelerating the development of innovative therapies. By integrating Harbour Mice®, HBICE®, HCAb PLUSTM, a single B-cell cloning platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit . SOURCE Harbour BioMed 21% more press release views with Request a Demo

Executive Change

11 Jun 2026

·www.fiercepharma.com

J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win

Johnson & Johnson has revealed data from a trial which could pave the way for a label expansion which would make Imaavy the first approved treatment for warm autoimmune hemolytic anemia. Last year, Johnson & Johnson arrived late to the party with Imaavy as the third FcRn blocker approved since 2021 to treat patients with generalized myasthenia gravis (gMG). But J&J has hopes for the monoclonal antibody in several other indications, including one rare disease in which it appears to be setting the pace—warm autoimmune hemolytic anemia (wAIHA). On Thursday, the company unveiled data from a pivotal phase 2/3 trial which could pave the way for a label expansion for Imaavy.In the Energy study, Imaavy worked quickly and elicited a statistically significant durable red blood-cell count response in patients with wAIHA, a life-threatening disorder which has no approved therapies. There is an urgent unmet need in the indication, where patients to rely on corticosteroids and immunosuppressive therapies which do not address the underlying cause of the disorder, according to J&J.The trial, which included 115 participants who were randomized 1:1:1 to receive two different doses of Imaavy or placebo, showed that three times as many patients who were infused with a 30 mg/kg dose of Imaavy achieved durable hemoglobin (Hgb) levels versus those on placebo after 24 weeks. The primary endpoint of the study was defined as an increase from baseline in Hgb of at least 2 g/dL and an Hgb concentration of at least 10 g/dL for at least 28 days without the need for rescue therapy or alterations in background treatment. Nearly two-thirds of treated patients achieved both of these targets by Week 24, J&J said.“Achieving hemoglobin improvements this quickly and at this scale is important in clinical practice, as it could help improve the debilitating fatigue that people living with warm autoimmune hemolytic anemia experience,” Bruno Fattizzo, M.D., of the Department of Oncology and Hematology-Oncology at the University of Milan, Italy, said in a release.Changes in patient-reported fatigue were seen as early as Week 2 in the trail and sustained throughout the treatment period, which was a key secondary endpoint. Another secondary objective, reductions in steroid use, also was achieved, J&J said. Imaavy also demonstrated a safety profile consistent with its use in gMG.J&J has already submitted for approval in the indication at the 30 mg/kg dose, gaining an FDA priority review designation in April, becoming the first to do so in the indication. The key to Imaavy’s effectiveness in the indication is its “immunoselective approach,” according to J&J’s Disease Area Leader for Autotibody and Rheumatology, Leonard Dragone, M.D., Ph.D.Imaavy “targets the underlying autoantibodies driving disease while preserving key immune functions, which is important for people living with this disease who frequently suffer with comorbid conditions,” he said in the release.J&J acquired Imaavy in its $6.5 billion buyout of Momenta Pharmaceuticals in 2020. The company has tabbed the treatment with peak sales potential of $5 billion or more and is investigating its use in a host of autoimmune disorders including Sjogren’s disease, hemolytic disease of the fetus and newborn and fetal neonatal alloimmune thrombocytopenia. Each of the programs are in phase 3 testing and have received FDA fast-track designation. J&J also has advanced Imaavy to phase 3 in chronic inflammatory demyelinating polyneuropathy and to phase 2 in systemic lupus erythematosus and idiopathic inflammatory myopathy.Last year, after coming up short in a phase 2a trial, the company bailed on its attempt to advance Imaavy as a combo agent in rheumatoid arthritis.Beating J&J to the finish line with FcRn blockers to treat gMG were argenx, which gained its approval for Vyvgart in 2021 and reported its sales at $4.2 billion in 2025, and UCB, which scored an FDA nod for Rystiggo in 2023 and reported its 2025 sales at 332 million euros ($375 million). J&J has yet to divulge sales of Imaavy, which it launched in April of last year, with the broadest label in the indication.

Clinical ResultPhase 3Drug ApprovalPhase 2Priority Review

11 Jun 2026

·allsci.com

TG Therapeutics aiming to expand Briumvi to myasthenia gravis after positive early data

TG Therapeutics (Nasdaq: TGTX) reported Phase I data showing that subcutaneous ublituximab (Briumvi), its glycoengineered anti-CD20 B-cell depleting antibody, produced clinically meaningful improvements in myasthenia gravis (MG) patients. The firm indicated that a Phase II trial will be initiated testing a sequential treatment strategy pairing an FcRn inhibitor for rapid symptom control followed by ublituximab for sustained B-cell depletion. TG is intent on expanding Briumvi beyond its approved multiple sclerosis indication into a generalized MG market that has grown substantially more competitive. The Phase II design — using argenx’s Vyvgart (efgartigimod alfa) as an induction agent before randomizing to ublituximab or placebo — is an unusual attempt to combine two mechanistically distinct drug classes in a sequential regimen. Trial data The Phase I cohort enrolled 11 adults with acetylcholine receptor antibody-positive MG (mean age 74; mean baseline MG-ADL 8.24), receiving subcutaneous ublituximab at exposures demonstrated to be at least equivalent to the approved intravenous regimen. At Week 24, 82% of patients achieved the minimal clinically important difference in MG-ADL (defined as a ≥2-point decrease), with a median time to MCID of 30 days. Mean MG-ADL improvement was 4.6 points. The safety profile was described as generally consistent with the established intravenous Briumvi profile in MS. These are small-sample, uncontrolled data and should be interpreted with caution; the absence of a comparator arm precludes conclusions about relative efficacy. The Phase II trial, now enrolling approximately 120 patients, uses a single induction cycle of efgartigimod (four weekly infusions), then randomizes MG-ADL responders 1:1 to intravenous ublituximab or placebo for 24 weeks. The primary endpoint is time to clinical worsening, defined as a ≥2-point MG-ADL increase or myasthenic crisis requiring hospitalization. A 72-week open-label extension follows. Competitive context The MG treatment landscape is crowded with approved FcRn inhibitors — argenx’s Vyvgart, Johnson & Johnson’s Imaavy (nipocalimab), and UCB’s Rystiggo (rozanolixizumab) — as well as complement inhibitors and, in late-stage development, BCMA-directed CAR-T therapies from Cartesian Therapeutics (Nasdaq: RNAC) and Kyverna Therapeutics (Nasdaq: KYTX). Ublituximab’s proposed differentiation rests on durable B-cell depletion as a maintenance strategy following FcRn-mediated rapid IgG reduction, a hypothesis the Phase II is designed to test. Cross-trial comparisons are limited by differences in patient populations, trial design, and endpoints. The Phase II is described as potentially registration-directed, though TG has cautioned that a successful result would not automatically qualify as a registrational study. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

Phase 2Phase 1Clinical ResultImmunotherapyCell Therapy

100 Deals associated with Rozanolixizumab

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14919

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Thrombocytopenia	Canada	UCB SA	01 Mar 2025
Myasthenia Gravis	United States	UCB, Inc.	26 Jun 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myasthenia Gravis, Ocular	Phase 3	United States	UCB Biopharma SRL	27 May 2026
Myelin oligodendrocyte glycoprotein antibody-associated disease	Phase 3	United States	UCB Biopharma SRL	02 Feb 2022
Myelin oligodendrocyte glycoprotein antibody-associated disease	Phase 3	Japan	UCB Biopharma SRL	02 Feb 2022
Myelin oligodendrocyte glycoprotein antibody-associated disease	Phase 3	Australia	UCB Biopharma SRL	02 Feb 2022
Myelin oligodendrocyte glycoprotein antibody-associated disease	Phase 3	Belgium	UCB Biopharma SRL	02 Feb 2022
Myelin oligodendrocyte glycoprotein antibody-associated disease	Phase 3	Brazil	UCB Biopharma SRL	02 Feb 2022
Myelin oligodendrocyte glycoprotein antibody-associated disease	Phase 3	Czechia	UCB Biopharma SRL	02 Feb 2022
Myelin oligodendrocyte glycoprotein antibody-associated disease	Phase 3	France	UCB Biopharma SRL	02 Feb 2022
Myelin oligodendrocyte glycoprotein antibody-associated disease	Phase 3	Germany	UCB Biopharma SRL	02 Feb 2022
Myelin oligodendrocyte glycoprotein antibody-associated disease	Phase 3	Greece	UCB Biopharma SRL	02 Feb 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06720714 (CTgov)	Phase 1	-	15	Rozanolixizumab	yjegmjjzro(iygjxctfeb) = crnpwzmutd mewieojhvc (edqvphoiia, NA) View more	-	04 Jun 2026
MDA2026	Not Applicable	Myasthenia Gravis anti-acetylcholine receptor antibody-positive \| anti-muscle-specific tyrosine kinase antibody-positive	26	Rozanolixizumab + Rozanolixizumab (gMG)	bchtaeynsx(itpatculjg) = treotqireu gguqhsjmsf (octjfvgrdz ) View more	Positive	08 Mar 2026
NCT03971422 (MycarinG, Pubmed \| J Neurol)	Phase 3	Myasthenia Gravis	200	Rozanolixizumab 7 mg/kg	dmxixzoisr(ckbtwfjtvv) = dlupznlwjn imzcoaoxly (inbfwtakyt ) View more	Positive	01 Dec 2025
				Rozanolixizumab 10 mg/kg	dmxixzoisr(ckbtwfjtvv) = tzztbkdzth imzcoaoxly (inbfwtakyt ) View more
NCT05681715 (MG0020, Pubmed \| J Neurol)	Phase 3	Myasthenia Gravis	55	Rozanolixizumab	yzdxfjjxuk(bmqeasolhf) = edosvzntox bomrxwkqum (kxxcueyetv ) View more	Positive	01 Oct 2025
NCT03971422 (MycarinG, Pubmed \| Eur J Neurol)	Phase 3	Myasthenia Gravis	164	Rozanolixizumab 7 mg/kg	ipajdtwrzb(tyeqxxhgcb) = ritxpkakuj jjkwiitwpf (dtbcyymzhm ) View more	Positive	01 Aug 2025
				Rozanolixizumab 10 mg/kg	ipajdtwrzb(tyeqxxhgcb) = cjacjyqwhj jjkwiitwpf (dtbcyymzhm ) View more
NCT04650854 (MG0007, EAN2025)	Phase 3	Myasthenia Gravis	188	Rozanolixizumab 7mg/kg	snzyodxzqr(hhdlxgtlms) = iytdlmevpt jaoloqivor (jagclpdbmz ) View more	Positive	21 Jun 2025
NCT03971422 (MycarinG, EAN2025 \| MDA2025)	Phase 3	Myasthenia Gravis	200	Rozanolixizumab 7mg/kg	-	Positive	21 Jun 2025
				Rozanolixizumab 10mg/kg
NCT04875975 (CTgov)	Phase 2	Autoimmune Encephalitis	12	Placebo	edjxlsiezx = ynkqljqkiy hgwnwdmzka (roqxngdnen, iddcdlpulu - mlhyjcufyy) View more	-	31 May 2025
NCT05681715 (MG0020, CTgov)	Phase 3	Myasthenia Gravis	62	RLZ SRD (Period 1: RLZ SRD)	nuwldpxuik = dptbmgxqwm vdquaukedr (skpieokjkc, qjzocvabis - rdlmohlbql) View more	-	07 May 2025
				RLZ (Period 1: RLZ MP)	nuwldpxuik = cihokknjkn vdquaukedr (skpieokjkc, oqkqpkrver - nbymbulacv) View more
NCT04650854 (MG0007, CTgov)	Phase 3	Myasthenia Gravis	165	Rozanolixizumab (Rozanolixizumab ~7 mg/kg)	wclasvkelv = ntghpnumli ebblwyxqmp (kgsyvgvihw, wbkfxvsrry - lbrhvvntty) View more	-	18 Apr 2025
				Rozanolixizumab (Rozanolixizumab ~10 mg/kg)	wclasvkelv = mucktvllor ebblwyxqmp (kgsyvgvihw, zupqbvykcz - tncxeoibgr) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis